Public notice

No. Title Writer Date Inquiry
9 (주)아이비스바이오 임시 주주 총회
관리자 23.10.13 Inquiry : 264
관리자 23.10.13 264
8 A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders.
관리자 23.05.19 Inquiry : 414
관리자 23.05.19 414
7 Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury
관리자 23.01.17 Inquiry : 508
관리자 23.01.17 508
6 3,6′- and 1,6′-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation
관리자 23.01.17 Inquiry : 474
관리자 23.01.17 474
5 Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis.
관리자 23.01.17 Inquiry : 500
관리자 23.01.17 500
4 Researches on immunomodulatory imides drug development under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, Int J Mol Sci. (July 31, 2021).
관리자 23.01.17 Inquiry : 517
관리자 23.01.17 517
3 The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, ACS P
관리자 23.01.17 Inquiry : 487
관리자 23.01.17 487
2 Research on the immunomodulatory imide drugs development under the Cooperative Research and Development Agreement(CRADA) with the National Institutes of Health(NIH) have been published in the peer-reviewed publication, Frontiers in Neuroscience(March 2)
관리자 23.01.17 Inquiry : 458
관리자 23.01.17 458
1 The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, eLife
관리자 23.01.17 Inquiry : 458
관리자 23.01.17 458